Hypoaldosteronism secondary prevention

Hypoaldosteronism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypoaldosteronism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypoaldosteronism secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hypoaldosteronism secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypoaldosteronism secondary prevention
CDC on Hypoaldosteronism secondary prevention
Hypoaldosteronism secondary prevention in the news
Blogs on Hypoaldosteronism secondary prevention
Directions to Hospitals Treating Hypoaldosteronism
Risk calculators and risk factors for Hypoaldosteronism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Effective measures for the secondary prevention of hypoaldosteronism include liberal salt intake of 4gm/day (to increase plasma sodium concentration), decreasing potassium intake and avoidance of drugs that affects renin angiotensin aldosterone system (RAAS) such as ACE inhibitors, ARBs, potassium sparing diuretics and β-Adrenergic receptor blockers.

Secondary Prevention

• Effective measures for the secondary prevention of hypoaldosteronism include:
  • Low potassium intake
  • Salt intake of 4gm/day
  • Avoid drugs affecting the renin angiotensin aldosterone system (RAAS) such as:
    • ACE inhibitors
    • Angiotensinogen receptor blocker
    • Potassium sparing diuretics
    • β-Adrenergic receptor blockers